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Under normal circumstances, the 
cells of the immune system (T cells, 
B cells, and other lymphocytes) 
cooperate to police our bodies for 
evidence of disease, mounting highly 
coordinated attacks against foreign 
invaders and cancerous cells. However, 
the immune system can occasionally 
become deranged, directing its arsenal 
against friend not foe, to attack 
healthy body tissues—a condition 
called autoimmunity. Fortunately, 
autoimmunity is rare, because the 
regulatory arm of the immune system 
works to suppress inappropriate 
inflammatory flare-ups before they 
evolve into full-blown conflagrations.
One crucial component of the 
regulatory immune system is a subset 
of T cells called “regulatory T cells.” 
Deficiencies in this population of cells 
can cause or exacerbate autoimmunity; 
therefore, scientists are trying to bolster 
the numbers or functional capacity of 
regulatory T cells to help prevent or 
treat autoimmunity. In a new study, 
Kristian Andersen, Tracey Butcher, 
and Alexander Betz report on their 
technique for generating regulatory 
T cells that can suppress disease in an 
animal model of autoimmune arthritis. 
Importantly, this approach may prove 
to be generally applicable to other 
autoimmune diseases.
Regulatory T cells and autoimmune 
pro-inflammatory T cells respond to the 
same kinds of stimuli, but regulatory 
T cells act to suppress inflammation. 
This difference in activity is conferred 
in part by the expression of the 
transcription factor Foxp3, which is 
thought to control expression of the 
anti-inflammatory phenotype—scientists 
have found that forcing expression of 
Foxp3 can convert a pro-inflammatory T 
cell into a regulatory T cell. Therefore, 
one experimental strategy to treat 
autoimmune diseases involves extracting 
bulk populations of T cells, modifying 
them by forcing Foxp3 expression, 
and then readministering them to 
the animal—where they should, in 
theory, suppress disease progression. 
Unfortunately, researchers have had 
mixed success using this approach to 
treat animal models of autoimmune 
diseases; it worked for autoimmune 
colitis, but not for other disease models 
such as collagen-induced arthritis.
Andersen et al. wondered whether 
the failure of this method to suppress 
autoimmune arthritis could be 
attributed to alterations in the behavior 
of the modified T cells. To test this 
theory, they used a fluorescent dye 
to track the movements of the cells 
after they are returned to the mice. 
Whereas unmodified T cells migrated 
throughout the body, the Foxp3-
modified cells congregated in the liver. 
The authors explain that forcing Foxp3 
expression causes impaired expression 
of another T cell protein, l-selectin. 
l-selectin allows T cells to access many 
body tissues and is one of several tissue 
homing receptors that are expressed on 
T cells. It’s possible that forcing Foxp3 
expression changes the patterns of 
expression of other homing receptors 
on T cells; if this is the case, the cells 
may be forced to go to the liver, unable 
to provide systemic relief. 
Because forcing Foxp3 expression 
prevented the cells from reaching the 
tissues where autoimmune reactions 
occur, Andersen et al. reasoned that a 
method was needed to turn on Foxp3 
expression in the cells only when it is 
needed. They therefore took T cells 
from mice and inserted a genetic 
construct that produces a modified 
inducible version of Foxp3 protein that 
is only active in the presence of the 
drug tamoxifen. These cells behaved 
like unmodified T cells and spread 
throughout the body when returned 
to the animals. In fact, some of them 
even participated in autoimmune 
inflammatory processes when the authors 
experimentally induced autoimmune 
arthritis. But, as soon as Foxp3 function 
was turned on by tamoxifen treatment, 
the cells that had been participating in 
the inflammation switched sides and 
started suppressing the disease.
Andersen et al. have figured out how 
to infiltrate rogue groups of T cells with 
undercover agents and then signal them 
to when it’s time to act. Importantly, 
these undercover regulatory cells 
do not suppress immune responses 
that are initiated after their Foxp3 
expression has been turned on. This 
means they likely won’t cause systemic 
immunosuppression, because they 
only dampen autoattacks they helped 
launch. However, as an additional safety 
measure, these cells could be engineered 
to express suicide genes. This would 
ensure that they are eliminated after 
they have served their purpose in 
suppressing an autoimmune flare-up.
A major advantage of the authors’ 
innovation is that it allows for 
the generation of disease-specific 
regulatory T cells without pre-existing 
knowledge of the factors that trigger 
an immune response for a given 
disease. This approach could not 
only drastically simplify therapeutic 
options for autoimmune diseases, but 
additionally figure in efforts to treat 
transplant rejection, which also results 
from undesired immune responses.
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The addition of tamoxifen causes a genetically engineered, inducible Foxp3 to move from the 
cytoplasm, where it is inactive (left), to the nucleus (right), where it can reprogram the cell to 
gain a regulatory phenotype.